Multiple MyelomaPhase 2DREAMM 14NCT05064358
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2 study testing Belantamab mafodotin in people with Multiple Myeloma, run by GlaxoSmithKline at 77 sites in 18 countries.
Trial summary
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Myeloma
- What is being tested?
- Belantamab mafodotin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 177 participants
- Where
- 77 sitesin 18 countries
- Study dates
- 3 Mar 2022to 10 Feb 2026
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant must be 18 years of age inclusive at the time of signing the informed consent form (ICF).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Histologically or cytologically confirmed diagnosis of MM and a. Has undergone stem cell transplant or is considered transplant ineligible, and b. Has failed at least 3 prior lines of anti-myeloma therapies, including an anti-cluster of differentiation (CD)38 antibody (e.g., daratumumab) alone or in combination and is refractory to an immunomodulatory agent (e.g., lenalidomide, pomalidomide) and a proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib).
- France specific: participants have failed at least 4 prior lines of anti-myeloma therapies
- Participant has measurable disease per modified IMWG criteria.
- Life expectancy of at least 6 months, in the opinion of the investigator.
Show all 9Show fewer
- Male and female participants agree to abide by protocol-defined contraceptive requirements.
- Participant is capable of giving signed informed consent.
- Participant meets country-specific inclusion criteria described in the protocol.
Who cannot join
- Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes), or active plasma cell leukemia at the time of screening.
- Current corneal epithelial disease, except nonconfluent superficial punctate keratitis (SPK).
- Evidence of active mucosal or internal bleeding.
- Presence of an active renal condition.
- Any serious and/or unstable pre-existing medical condition, psychiatric disorder, or other conditions that could interfere with the participant's safety, obtaining informed consent, or compliance with the study procedures.
- Malignancies other than the disease under study, except for any other malignancy from which the participant has been disease free for >2 years and, will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy (MM). Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction.
Show all 23Show fewer
- Evidence of cardiovascular risk as per the protocol criteria.
- Pregnant or lactating female.
- Active infection requiring antibiotic, antiviral, or antifungal treatment.
- Known human immunodeficiency virus (HIV) infection, unless the criteria in protocol can be met.
- Hepatitis B and C will be excluded unless the criteria in protocol can be met.
- Cirrhosis or current unstable liver or biliary disease.
- Alanine aminotransferase (ALT) >2.5× upper limit of normal (ULN).
- Total Bilirubin >1.5×ULN.
- Systemic anti-MM therapy within <=14 days or 5 half-lives, whichever is shorter.
- Systemic therapy with high dose steroids within <=14 days before the first dose of study treatment.
- Prior allogenic stem cell transplant.
- Prior treatment with a monoclonal antibody <=30 days before the first dose of study treatment. Use of monoclonal antibodies for serious conditions unrelated to multiple myeloma, such as COVID, may be permitted.
- Prior treatment with an anti-B cell maturation antigen (BCMA) targeted therapy or hypersensitivity reactions to any components of the study treatment.
- Treatment with an antibody-drug conjugate.
- Participant has received any major surgery <=4 weeks before the first dose of study treatment. An exception may be allowed for bone stabilizing surgery.
- Inadequate bone marrow reserve or organ functions as demonstrated by any of the following: a. Absolute neutrophil count <1.0×10^9/L, b. Hemoglobin <8 gram/deciliter (g/dL), c. Platelet count <50×10^9/L, d. Spot urine (albumin/creatinine ratio) >500 milligram/gram (mg/g), e. Estimated glomerular filtration rate (eGFR) <30 milliliter per minute per 1.73 meter square (mL/min/1.73m^2).
- UK specific: a. Absolute neutrophil count <1.5×10^9/L, c. Platelet count <75×10^9/L
Trial locations and contacts
77 sites in 18 countries.
77 sites in 18 countries
Poland9 sites
GSK Investigational Site
Bydgoszcz, 85-168
GSK Investigational Site
Gdansk, 80-214
GSK Investigational Site
Katowice, 40-519
GSK Investigational Site
Lublin, 20-081
GSK Investigational Site
Poznan, 60-569
GSK Investigational Site
Torun, 87-100
GSK Investigational Site
Wałbrzych, 58-309
GSK Investigational Site
Warsaw, 02-781
GSK Investigational Site
Wroclaw, 50-367
Italy7 sites
GSK Investigational Site
Alessandria, 15121
GSK Investigational Site
Ascoli Piceno, 63100
GSK Investigational Site
Ferrara, 44124
GSK Investigational Site
Genova, 16132
GSK Investigational Site
Meldola FC, 47014
GSK Investigational Site
Reggio Emilia, 42123
GSK Investigational Site
Rimini, 47900
Spain7 sites
GSK Investigational Site
Albacete, 02006
GSK Investigational Site
Barcelona, 08026
GSK Investigational Site
Córdoba, 140044
GSK Investigational Site
Girona, 17007
GSK Investigational Site
Oviedo, 33011
GSK Investigational Site
Terrassa - Barcelona, 08221
GSK Investigational Site
Valencia, 46010
United States6 sites
GSK Investigational Site
Chattanooga, Tennessee, 37404
GSK Investigational Site
Houston, Texas, 77090
GSK Investigational Site
Kansas City, Missouri, 64114
GSK Investigational Site
Nashville, Tennessee, 37203
GSK Investigational Site
New York, New York, 10065
GSK Investigational Site
West Palm Beach, Florida, 33401
Brazil6 sites
GSK Investigational Site
Joinville, 89201-260
GSK Investigational Site
Porto Alegre, 90850-170
GSK Investigational Site
Rio de Janeiro, 22271-110
GSK Investigational Site
Salvador, 41253-190
GSK Investigational Site
São Paulo, 01236-030
GSK Investigational Site
São Paulo, 04537-080
Argentina5 sites
GSK Investigational Site
Buenos Aires, C1181ACH
GSK Investigational Site
Capital Federal, C1426ANZ
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, 1414
GSK Investigational Site
Pilar, B1629AHJ
GSK Investigational Site
Rosario, S2002
Taiwan5 sites
GSK Investigational Site
Taichung, 404
GSK Investigational Site
Taichung, 40705
GSK Investigational Site
Tainan, 704
GSK Investigational Site
Taipei, 100
GSK Investigational Site
Taipei, 112
Australia4 sites
GSK Investigational Site
East Melbourne, Victoria, 3002
GSK Investigational Site
Liverpool, New South Wales, 2170
GSK Investigational Site
Newcastle, New South Wales, 2298
GSK Investigational Site
Woodville, South Australia, 5011
Germany4 sites
GSK Investigational Site
Cottbus, 03048
GSK Investigational Site
Dresden, 01307
GSK Investigational Site
Greifswald, 17475
GSK Investigational Site
Hamburg, 22763
Greece4 sites
GSK Investigational Site
Athens, 106 76
GSK Investigational Site
Athens, 11528
GSK Investigational Site
Athens, 12462
GSK Investigational Site
Rio Patras, 26504
South Korea4 sites
GSK Investigational Site
Hwasun, 58128
GSK Investigational Site
Pusan, 49241
GSK Investigational Site
Seoul, 03080
GSK Investigational Site
Seoul, 06591
Thailand4 sites
GSK Investigational Site
Bangkok, 10210
GSK Investigational Site
Bangkok, 10330
GSK Investigational Site
Chiang Mai, 50200
GSK Investigational Site
Khon Kaen, 40002
France3 sites
GSK Investigational Site
Avignon, 84902
GSK Investigational Site
Nice, 06189
GSK Investigational Site
Orléans, 45100
United Kingdom3 sites
GSK Investigational Site
Leicester, LE1 5WW
GSK Investigational Site
London, W12 0HS
GSK Investigational Site
Stoke-on-Trent, ST4 6QG
Ireland2 sites
GSK Investigational Site
Dublin, 8
GSK Investigational Site
Dublin, D09 V2N0
Mexico2 sites
GSK Investigational Site
Mexico City, 03100
GSK Investigational Site
Mexico City, 03720
About this study
Official title: A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-agent Belantamab Mafodotin (GSK2857916) in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM-14)
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
- Conditions
- Multiple Myeloma
- Being tested
- Belantamab mafodotin
- Keywords
- Antibody drug conjugate, Belantamab mafodotin, BLENREP, DREAMM14, GSK2857916, Alternative dosing, Relapsed or refractory multiple myeloma, RRMM
- Medical subject headings
- Multiple Myeloma, Recurrence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Belantamab mafodotinDrug
Belantamab mafodotin will be administered.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1: Participants receiving belantamab mafodotin at dose level (DL) 1 | Experimental | Not described Receives: Drug: Belantamab mafodotin |
| Cohort 2: Participants receiving belantamab mafodotin at DL 2 | Experimental | Not described Receives: Drug: Belantamab mafodotin |
| Cohort 3: Participants receiving belantamab mafodotin at DL 3 | Experimental | Not described Receives: Drug: Belantamab mafodotin |
| Cohort 4: Participants receiving belantamab mafodotin at DL 4 | Experimental | Not described Receives: Drug: Belantamab mafodotin |
| Cohort 5: Participants receiving belantamab mafodotin at DL4 with alternative dose modification | Experimental | Not described Receives: Drug: Belantamab mafodotin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale
The KVA scale is based on the evaluation of corneal changes using slit lamp examination. This scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Measured: Up to 29.5 months
Secondary outcomes (30)
Number of Participants With Corneal Events up to Week 16
The number of participants with corneal events were assessed using KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Measured: Up to week 16
Incidence Rate of Corneal Events by Grade (KVA Scale)
Incidence rate of corneal events is defined as the percentage of participants with corneal events by grade according to the KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Measured: Up to 152 weeks
Exposure Adjusted Incidence Rate of Corneal Events as Per CTCAE Grade
Exposure adjusted incidence rate of corneal events is defined as the number of participants with corneal events divided by the total exposure time for all participants at risk in the treatment group. Incidence rate for corneal events was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity. The number of participants with Grades 3,4, and 5 are presented.
Measured: Up to 152 weeks
Median Duration of All the Dose Delays
Median duration of dose delays is defined as the median duration in time of all the dose delays in the respective treatment group. Duration of delays is defined as period from the expected start date of dose to actual start date of current dose.
Measured: Up to 152 weeks
Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Corneal Events
The percentage of participants that required dose reduction, dose interruption/delay, permanent treatment discontinuation due to corneal events were evaluated using KVA Scale. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Measured: Up to 152 weeks
Cumulative Incidence of Grade 2 or Above Corneal Events (KVA Scale)
Cumulative incidence of Grade 2 or above corneal events is defined as the percentage of corneal events of Grade 2 or above, as assessed using the KVA scale, within a specific time interval. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Measured: At 3 months, 6 months, 9 months and 12 months
Toxicity Index (TI)
Toxicity Index is a composite score derived from the severity grades of adverse events (AEs) reported during the study, based on the Common Terminology Criteria for Adverse Events (CTCAE). A participant's score is calculated as a function of the ordered toxicity grades, represented in descending order by sequence, on a scale of 0-6, where 0 represents no toxicity and 6 represents the highest toxicity. CTCAE grades are defined as follows: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe or medically significant but not immediately life-threatening), Grade 4 (Life-threatening consequences), and Grade 5 (Death related to AE). Higher grades indicate greater toxicity severity.
Measured: Up to 152 weeks
Duration of Corneal Events of Grade 2 or Above
Duration of corneal events is defined for each participant as the sum of duration of all the corneal AEs. The duration is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first time resolution to baseline, Grade 1 or below. It required at least one day gap between the resolution of all events from first occurrence to the onset of next occurrence.
Measured: Up to 152 weeks
Percentage of Time on Study With Grade 2 or Above Corneal Events
It is defined as the percentage of time that a participant has corneal events out of the total time that a participant is on the study. Time with corneal events is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first-time resolution to baseline, Grade 1 or below.
Measured: Up to 152 weeks
Number of Participants With Change in Best Corrected Visual Acuity Test (BCVA) Scores
Change in BCVA is defined as change in logarithm of the minimum angle of resolution (logMAR) units compared with baseline or the first visit after the cataract surgery. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any change from baseline categories is presented for right and left eyes. No change/improved vision is defined as a change from baseline <0.1; a possible worsened vision is defined as a change from baseline >=0.1 to <=0.3; a definite worsened vision is defined as a change from baseline >0.3 logMAR score. Improvement in BCVA is represented by a reduction in logMAR score from baseline, while worsening in BCVA is represented by an increase in logMAR score from baseline.
Measured: Baseline (Day 1) and up to 152 weeks
Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response [VGPR], complete response [CR] and stringent complete response [sCR]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 h.
Measured: Up to 152 weeks
Percentage of Participants With a Confirmed VGPR or Better (i.e., VGPR, CR, and sCR)
Percentage of participants with a confirmed VGPR or better defined as percentage of participant with confirmed VGPR, CR, and sCR, according to the 2016 IMWG response criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 h.
Measured: Up to 152 weeks
Time to Response (TTR)
TTR defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better), according to the 2016 IMWG response criteria. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 h.
Measured: Up to 152 weeks
Duration of Response (DoR)
DoR defined as the time from first documented evidence of PR or better until disease progression (PD) among responders according to the 2016 IMWG response criteria or death due to any cause. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 h. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of >= 0.5 g/dL; Serum M-protein increase >= 1 g/dL if the lowest M-component was >=5 g/dL; Urinary M-protein (absolute increase must be >= 200 mg per 24 h).
Measured: Up to 152 weeks
Time to Progression (TTP)
TTP defined as the time from randomization until the earliest date of documented PD or death due to PD, according to the 2016 IMWG response criteria. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of >= 0.5 g/dL; Serum M-protein increase >= 1 g/dL if the lowest M-component was >=5 g/dL; Urinary M-protein (absolute increase must be >= 200 mg per 24 h).
Measured: Up to 152 weeks
Progression Free Survival (PFS)
PFS defined as the time from randomization until the earliest date of documented PD, according to the 2016 IMWG response criteria, or death due to any cause. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of >= 0.5 g/dL; Serum M-protein increase >= 1 g/dL if the lowest M-component was >=5 g/dL; Urinary M-protein (absolute increase must be >= 200 mg per 24 h).
Measured: Up to 152 weeks
Overall Survival (OS)
OS defined as the time from randomization until the date of death due to any cause.
Measured: Up to 152 weeks
Percentage of Participants With AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard Medical Dictionary for Regulatory Activities (MedDRA).
Measured: Up to 152 weeks
Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Any AEs
Percentage of participants requiring dose reduction, dose interruption/delay, permanent treatment discontinuation due to any AEs were presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard MedDRA.
Measured: Up to 152 weeks
Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Blood samples were collected for the analysis of hematology parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.
Measured: Up to 152 weeks
Number of Participants With Worst-Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Blood samples were collected for the analysis of clinical chemistry parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.
Measured: Up to 152 weeks
Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Measured: Baseline (Day 1) and up to 152 weeks
Titers of ADAs Against Belantamab Mafodotin
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
Measured: Up to 152 weeks
Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC)
Plasma samples were collected for PK analysis for belantamab mafodotin antibody-drug conjugate (ADC).
Measured: Cycle(C)1 Day(D) 1 Pre-dose, End of Infusion (EOI), Start of Infusion (SOI) + 2 hours (H); C1D2 SOI+24H; C1D4; C1D8-15
Concentration at 21 Days for Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
Measured: At 21 days
Average Concentration Over 21 Days (Cavg) for Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
Measured: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21
Area Under the Concentration-time Curve (AUC) (0-504h) of Belantamab Mafodotin ADC
Plasma samples were collected to determine the area under the concentration-time curve (AUC) (0-504h) of Belantamab mafodotin ADC.
Measured: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21
Half-life (t1/2) of Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis of Belantamab mafodotin ADC
Measured: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Clearance (CL) for Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
Measured: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Steady-state Volume of Distribution (Vss) for Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
Measured: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2021
- Study start3 Mar 2022
- Primary completion19 Aug 2024
- Study completion10 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Multiple MyelomaStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Belantamab mafodotin will be administered using various dosing regimens.
- Masking
- None (open label)
- Enrolment
- 177 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05064358
- Sponsor's protocol ID
- 209628
- Other IDs
- 2021-004151-16, 2023-508213-16, 2023
- Acronym
- DREAMM 14
- Status last verified
- Apr 2026
- First submitted
- 22 Sep 2021
- Last updated
- 5 May 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About\_GSK\_Patient\_Level\_Data\_Sharing\_Final\_13July2023.pdf.
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-agent Belantamab Mafodotin (GSK2857916) in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM-14)
- ClinicalTrials.gov ID
- NCT05064358
- Acronym / sponsor ID
- DREAMM 14 / 209628
- Conditions
- Multiple Myeloma
- Keywords
- Antibody drug conjugate, Belantamab mafodotin, BLENREP, DREAMM14, GSK2857916, Alternative dosing, Relapsed or refractory multiple myeloma, RRMM
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 177 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- 3 Mar 2022 (actual)
- Primary completion
- 19 Aug 2024 (actual)
- Study completion
- 10 Feb 2026 (actual)
- First posted
- 1 Oct 2021 (actual)
- Results
- Posted 7 Oct 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 5
- Model description
- Belantamab mafodotin will be administered using various dosing regimens.
| Arm | Type | Receives |
|---|---|---|
| Cohort 1: Participants receiving belantamab mafodotin at dose level (DL) 1 | Experimental | Drug: Belantamab mafodotin |
| Cohort 2: Participants receiving belantamab mafodotin at DL 2 | Experimental | Drug: Belantamab mafodotin |
| Cohort 3: Participants receiving belantamab mafodotin at DL 3 | Experimental | Drug: Belantamab mafodotin |
| Cohort 4: Participants receiving belantamab mafodotin at DL 4 | Experimental | Drug: Belantamab mafodotin |
| Cohort 5: Participants receiving belantamab mafodotin at DL4 with alternative dose modification | Experimental | Drug: Belantamab mafodotin |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Participant must be 18 years of age inclusive at the time of signing the informed consent form (ICF).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Histologically or cytologically confirmed diagnosis of MM and a. Has undergone stem cell transplant or is considered transplant ineligible, and b. Has failed at least 3 prior lines of anti-myeloma therapies, including an anti-cluster of differentiation (CD)38 antibody (e.g., daratumumab) alone or in combination and is refractory to an immunomodulatory agent (e.g., lenalidomide, pomalidomide) and a proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib).
- France specific: participants have failed at least 4 prior lines of anti-myeloma therapies
- Participant has measurable disease per modified IMWG criteria.
Key exclusion criteria (23 listed)
- Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes), or active plasma cell leukemia at the time of screening.
- Current corneal epithelial disease, except nonconfluent superficial punctate keratitis (SPK).
- Evidence of active mucosal or internal bleeding.
- Presence of an active renal condition.
- Any serious and/or unstable pre-existing medical condition, psychiatric disorder, or other conditions that could interfere with the participant's safety, obtaining informed consent, or compliance with the study procedures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Belantamab mafodotinBelantamab mafodotin will be administered. | Drug | Cohort 1: Participants receiving belantamab mafodotin at dose level (DL) 1, Cohort 2: Participants receiving belantamab mafodotin at DL 2, Cohort 3: Participants receiving belantamab mafodotin at DL 3, Cohort 4: Participants receiving belantamab mafodotin at DL 4, Cohort 5: Participants receiving belantamab mafodotin at DL4 with alternative dose modification |
Primary outcome
Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale
Time frame: Up to 29.5 months
The KVA scale is based on the evaluation of corneal changes using slit lamp examination. This scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
30 secondary outcomes
Number of Participants With Corneal Events up to Week 16
Time frame: Up to week 16
Incidence Rate of Corneal Events by Grade (KVA Scale)
Time frame: Up to 152 weeks
Exposure Adjusted Incidence Rate of Corneal Events as Per CTCAE Grade
Time frame: Up to 152 weeks
Median Duration of All the Dose Delays
Time frame: Up to 152 weeks
Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Corneal Events
Time frame: Up to 152 weeks
Cumulative Incidence of Grade 2 or Above Corneal Events (KVA Scale)
Time frame: At 3 months, 6 months, 9 months and 12 months
Toxicity Index (TI)
Time frame: Up to 152 weeks
Duration of Corneal Events of Grade 2 or Above
Time frame: Up to 152 weeks
Percentage of Time on Study With Grade 2 or Above Corneal Events
Time frame: Up to 152 weeks
Number of Participants With Change in Best Corrected Visual Acuity Test (BCVA) Scores
Time frame: Baseline (Day 1) and up to 152 weeks
Objective Response Rate (ORR)
Time frame: Up to 152 weeks
Percentage of Participants With a Confirmed VGPR or Better (i.e., VGPR, CR, and sCR)
Time frame: Up to 152 weeks
Time to Response (TTR)
Time frame: Up to 152 weeks
Duration of Response (DoR)
Time frame: Up to 152 weeks
Time to Progression (TTP)
Time frame: Up to 152 weeks
Progression Free Survival (PFS)
Time frame: Up to 152 weeks
Overall Survival (OS)
Time frame: Up to 152 weeks
Percentage of Participants With AEs
Time frame: Up to 152 weeks
Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Any AEs
Time frame: Up to 152 weeks
Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Time frame: Up to 152 weeks
Number of Participants With Worst-Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Time frame: Up to 152 weeks
Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Time frame: Baseline (Day 1) and up to 152 weeks
Titers of ADAs Against Belantamab Mafodotin
Time frame: Up to 152 weeks
Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC)
Time frame: Cycle(C)1 Day(D) 1 Pre-dose, End of Infusion (EOI), Start of Infusion (SOI) + 2 hours (H); C1D2 SOI+24H; C1D4; C1D8-15
Concentration at 21 Days for Belantamab Mafodotin ADC
Time frame: At 21 days
Average Concentration Over 21 Days (Cavg) for Belantamab Mafodotin ADC
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21
Area Under the Concentration-time Curve (AUC) (0-504h) of Belantamab Mafodotin ADC
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21
Half-life (t1/2) of Belantamab Mafodotin ADC
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Clearance (CL) for Belantamab Mafodotin ADC
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Steady-state Volume of Distribution (Vss) for Belantamab Mafodotin ADC
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No. GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Related trials for Multiple Myeloma
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
77 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Belantamab mafodotin in people with Multiple Myeloma, run by GlaxoSmithKline at 77 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 77 sites in Poland, Italy, Spain, United States, Brazil and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Oct 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale (time frame: Up to 29.5 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.